 |
|
 |
|
|
|
|
 |
 |
 |
|
Ortec International, Inc. ("ORTC") is a development-stage tissue-engineering company developing and commercializing a proprietary skin regeneration product it calls Composite Cultured Skin ("CCS"). CCS is a permeable, bi-layered matrix that stimulates a unique growth environment for both dermal and epidermal skin cells. CCS is currently in clinical trials for treatment of donor site wounds and venous skin ulcers, and has completed a clinical trial under an Investigator's IDE using CCS for the treatment of chronic dermal skin ulcers in Epidermolysis Bullosa (EB) patients. We believe CCS may have wide commercial applications for the treatment of burns and diabetic skin ulcers, as well as for reconstructive and cosmetic surgery. The Company intends to file a Humanitarian Device Exemption (HDE) and launch CCS for the Epidermolysis Bullosa this year. We are initiating coverage on ORTC with a BUY rating, and recommend purchase by investors tolerant of the risks associated with micro-cap and small-cap equity investments.
SMALLCAPS RESEARCH
Initial Opinion (HTML) (03/25/99)